A. Wahlén

1.0k total citations
12 papers, 745 citations indexed

About

A. Wahlén is a scholar working on Pharmacology, Toxicology and Psychiatry and Mental health. According to data from OpenAlex, A. Wahlén has authored 12 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pharmacology, 3 papers in Toxicology and 3 papers in Psychiatry and Mental health. Recurrent topics in A. Wahlén's work include Cannabis and Cannabinoid Research (4 papers), Forensic Toxicology and Drug Analysis (3 papers) and Neonatal Health and Biochemistry (2 papers). A. Wahlén is often cited by papers focused on Cannabis and Cannabinoid Research (4 papers), Forensic Toxicology and Drug Analysis (3 papers) and Neonatal Health and Biochemistry (2 papers). A. Wahlén collaborates with scholars based in Sweden, United States and Netherlands. A. Wahlén's co-authors include Leo E. Hollister, Stig Agurell, J.‐E. Lindgren, Annika Ohlsson, H. K. Gillespie, Lars Farde, F.‐A. Wiesel, Paul Jansson, Göran Sedvall and Agneta Ohlsson and has published in prestigious journals such as Psychopharmacology, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

A. Wahlén

11 papers receiving 696 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Wahlén Sweden	9	537	241	192	99	95	12	745
Hampton Gillespie United States	11	558 1.0×	366 1.5×	127 0.7×	69 0.7×	92 1.0×	13	868
M Widman Sweden	14	520 1.0×	227 0.9×	178 0.9×	131 1.3×	41 0.4×	31	739
Howard Rowe United States	16	458 0.9×	250 1.0×	103 0.5×	61 0.6×	160 1.7×	29	852
Andreas M. Stadelmann Germany	10	418 0.8×	234 1.0×	89 0.5×	65 0.7×	62 0.7×	14	668
Martin Schnelle Germany	7	611 1.1×	178 0.7×	113 0.6×	119 1.2×	67 0.7×	8	818
Lin Aanonsen United States	8	519 1.0×	418 1.7×	87 0.5×	29 0.3×	36 0.4×	9	859
M Evans United Kingdom	17	191 0.4×	342 1.4×	61 0.3×	101 1.0×	86 0.9×	35	1.1k
Thomas Nadulski Germany	11	381 0.7×	165 0.7×	265 1.4×	162 1.6×	37 0.4×	18	632
Robert Martz United States	13	272 0.5×	176 0.7×	80 0.4×	49 0.5×	42 0.4×	25	590
R.B. Forney United States	15	303 0.6×	203 0.8×	92 0.5×	43 0.4×	23 0.2×	60	654

Countries citing papers authored by A. Wahlén

Since Specialization

Citations

This map shows the geographic impact of A. Wahlén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Wahlén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Wahlén more than expected).

Fields of papers citing papers by A. Wahlén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Wahlén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Wahlén. The network helps show where A. Wahlén may publish in the future.

Co-authorship network of co-authors of A. Wahlén

This figure shows the co-authorship network connecting the top 25 collaborators of A. Wahlén. A scholar is included among the top collaborators of A. Wahlén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Wahlén. A. Wahlén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Nordström, Anna, et al.. (1992). Pharmacokinetics of Raclopride Formulations. Clinical Pharmacokinetics. 22(2). 152–161. 10 indexed citations

Farde, Lars, et al.. (1989). The New Selective D2-dopamine Receptor Antagonist Raclopride—Pharmacokinetics, Safety and Tolerability in Healthy Males. International Clinical Psychopharmacology. 4(2). 115–126. 15 indexed citations

Farde, Lars, et al.. (1988). An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology. 94(1). 1–7. 94 indexed citations

Teunissen, M. W. E., A. Wahlén, E. Vinnars, & D. D. Breimer. (1984). Influence of alaproclate on antipyrine metabolite formation in man. European Journal of Clinical Pharmacology. 27(4). 447–452. 3 indexed citations

Wahlén, A., Douglas Westerlund, E Wahlin‐Boll, & Arne Melander. (1983). Influence of food intake on the bioavailability of zimeldine and its active metabolite, norzimeldine.. PubMed. 2(3). 175–81. 5 indexed citations

Ohlsson, Agneta, Jan‐Erik Lindgren, A. Wahlén, et al.. (1982). Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Journal of Mass Spectrometry. 9(1). 6–10. 78 indexed citations

Hægerstam, Glenn, et al.. (1982). Placebo in clinical drug trials--a multidisciplinary review.. PubMed. 4(4). 261–78. 13 indexed citations

Hollister, Leo E., H. K. Gillespie, Annika Ohlsson, et al.. (1981). Do Plasma Concentrations of Δ⁹‐Tetrahydrocannabinol Reflect the Degree of Intoxication?. The Journal of Clinical Pharmacology. 21(S1). 171S–177S. 123 indexed citations

Evers, Hans, et al.. (1981). Antithrombotic Effects of Lidocaine and Related Compounds on Laser‐Induced Microvascular Injury. Acta Anaesthesiologica Scandinavica. 25(1). 9–11. 32 indexed citations

10.

Ohlsson, A, et al.. (1981). Plasma levels of delta 9-tetrahydrocannabinol after intravenous, oral, and smoke administration.. PubMed. 34. 250–6. 13 indexed citations

11.

Ohlsson, Annika, J.‐E. Lindgren, A. Wahlén, et al.. (1980). Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology & Therapeutics. 28(3). 409–416. 359 indexed citations

12.

Wagner, Jonathan, et al.. (1976). [Regional myocardial perfusion redistribution through coronary drugs. II. Influence of dipyridamole and oxyfedrin on regional perfusion distribution].. PubMed. 65(3). 233–44.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact